Table 3– Comparison between previous antibiotic use and empirical choice for antibiotic therapy in patients with nosocomial pneumonia
Subjects nCBP#Pip/tazoCFP/CFZCFX/CROGlycopeptidesLinezolidA/CFQColistinCombination
Prior exposure to ATB
 No598212 (181)186 (138)66 (60)97 (68)117 (110)57 (51)50 (21)138 (131)37 (35)421
 Yes9140 (30)13 (11)8 (7)4 (4)23 (21)13 (11)2 (2)9 (7)4 (3)62
Previous ATB class
 CBP316 (5)2 (2)4 (3)0 (0)11 (9)6 (5)0 (0)3 (3)2 (1)18
 Pip/tazo2013 (10)0 (0)2 (2)1 (1)6 (6)2 (2)1 (1)2 (1)151 (1)
 Glycopeptides168 (5)0 (0)2 (2)14 (4)0 (0)0 (0)1 (1)2 (1)9
 Aminoglycosides137 (7)2 (2)1 (1)0 (0)5 (5)1 (1)0 (0)1 (0)1 (1)11
 A/C123 (3)5 (4)1 (1)0 (0)3 (3)0 (0)1 (1)0 (0)90 (0)
 CFP/CFZ85 (5)1 (1)0 (0)0 (0)0 (0)2 (1)0 (0)1 (1)0 (0)6
 CFX/CRO86 (4)2 (1)1 (1)1 (1)0 (0)2 (2)0 (0)1 (1)1 (1)6
 FQ53 (2)5 (0)0 (0)1 (1)3 (3)1 (1)0 (0)0 (0)0 (0)5
 Combination4524 (22)3 (3)4 (4)2 (2)14 (14)6 (5)1 (1)3 (2)354 (3)

  • Data are presented as total number of patients prescribed each antibiotic (number of times each antibiotic was given in combination with another), unless otherwise stated. The sums of the numbers do not correspond to the number of patients because a patient could receive more than one agent. CBP: carbapenem; Pip/tazo: piperacillin-tazobactam; CFP/CFZ: cefepime/ceftazidime; CFX/CRO: cefotaxime/ceftriaxone; A/C: amoxicillin-clavulanate; FQ: fluoroquinolones; ATB: antibiotic. #: imipenem, n = 120; meropenem, n = 164.